Phase 2 teclistamab bispecific BCMA/CD3 antibody trial in high-risk multiple myeloma

This open-label Phase 2 trial investigates sequencing of teclistamab, daratumumab, and talquetamab—with or without melphalan transplant—for newly diagnosed high-risk multiple myeloma patients stratified by minimal residual disease status. The study enrolls 1st or 2nd line patients at Little Rock under University of Arkansas oversight, exploring innovative bispecific antibody combinations for improved disease control.